住院内科患者静脉血栓栓塞症药物预防启动的相关因素:内科住院患者血栓与止血研究
该队列研究利用2016至2019年4家学术医疗中心成人内科住院患者的电子健康记录数据,纳入111550例次非中/全剂量抗凝住院,发现48520例次(43.5%)在入院当天或次日启动医院获得性静脉血栓栓塞症(HA-VTE)药物预防。调整后营养不良和慢性阻塞性肺疾病是最强临床预测因素,血小板减少和消化道出血史与启动几率降低相关,预测HA-VTE风险最高两个三分位组患者启动药物预防的几率低于最低三分位组。
要点
- 111550例次住院中48520例次(43.5%)在入院当天或次日启动HA-VTE药物预防。
- 营养不良和慢性阻塞性肺疾病是启动HA-VTE药物预防最强的临床预测因素。
- 预测HA-VTE风险最高两个三分位组启动药物预防几率低于最低三分位组。
核心结论
- 在未接受抗凝治疗的内科住院患者中,预测HA-VTE风险较高者及存在出血危险因素者在入院前2天内启动HA-VTE药物预防的比例较低。
- 原文指出,无法评估预测HA-VTE风险较高的患者未启动药物预防的原因。
研究设计与样本
- 采用电子健康记录数据的队列研究,纳入2016至2019年4家学术医疗中心成人内科住院患者。
- 共分析111550例次未接受中剂量或全剂量抗凝的住院。
主要发现
- 111550例次住院中48520例次(43.5%)在入院当天或次日接受HA-VTE药物预防。
- 调整年龄、性别、种族/民族和研究地点后,启动HA-VTE药物预防最强的临床预测因素为营养不良和慢性阻塞性肺疾病。
- 血小板减少和消化道出血史与HA-VTE药物预防启动几率降低相关。
- 预测HA-VTE风险第二三分位组患者启动药物预防的OR为0.84(95%CI 0.81-0.86),第三三分位组OR为0.95(95%CI 0.92-0.98),均低于第一三分位组。
局限性
- 原文指出,无法评估预测HA-VTE风险较高的患者未启动药物预防的原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although guidelines recommend risk assessment for hospital-acquired venous thromboembolism (HA-VTE) to inform prophylaxis decisions, studies demonstrate inappropriate utilization of pharmacoprophylaxis in hospitalized medical patients. Predictors of pharmacoprophylaxis initiation in medical inpatients remain largely unknown. OBJECTIVES: To determine factors associated with HA-VTE pharmacoprophylaxis initiation in adults hospitalized on medical services. METHODS: We performed a cohort study using electronic health record data from adult patients hospitalized on medical services at 4 academic medical centers between 2016 and 2019. Main measures were candidate predictors of HA-VTE pharmacoprophylaxis initiation, including known HA-VTE risk factors, predicted HA-VTE risk, and bleeding diagnoses present on admission. RESULTS: Among 111 550 admissions not on intermediate or full-dose anticoagulation, 48 520 (43.5%) received HA-VTE pharmacoprophylaxis on the day of or the day after admission. After adjustment for age, sex, race/ethnicity, and study site, the strongest clinical predictors of HA-VTE pharmacoprophylaxis initiation were malnutrition and chronic obstructive pulmonary disease. Thrombocytopenia and history of gastrointestinal bleeding were associated with decreased odds of HA-VTE pharmacoprophylaxis initiation. Patients in the highest 2 tertiles of predicted HA-VTE risk were less likely to receive HA-VTE pharmacoprophylaxis than patients in the lowest (first) tertile (OR, 0.84; 95% CI, 0.81-0.86 for the second tertile; OR, 0.95; 95% CI, 0.92-0.98 for the third tertile). CONCLUSION: Among patients not already receiving anticoagulants, HA-VTE pharmacoprophylaxis initiation during the first 2 hospital days was lower in patients with a higher predicted HA-VTE risk and those with risk factors for bleeding. Reasons for not initiating pharmacoprophylaxis in those with a higher predicted HA-VTE risk could not be assessed.
引用
- Repp AB, Sparks AD, Wilkinson K, et al. Factors associated with venous thromboembolism pharmacoprophylaxis initiation in hospitalized medical patients: the Medical Inpatients Thrombosis and Hemostasis study. J Thromb Haemost. 2024. PMID: 39260742. doi:10.1016/j.jtha.2024.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。